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Abstract
Background: Variation in genes involved in the innate immune response may play a role in the
predisposition to colorectal cancer (CRC). Several polymorphisms of the CARD15 gene (caspase
activating recruitment domain, member 15) have been reported to be associated with an increased
susceptibility to Crohn disease. Since the CARD15 gene product and other CARD proteins function
in innate immunity, we investigated the impact of germline variation at the CARD4, CARD8 and
CARD15 loci on the risk for sporadic CRC, using a large patient sample from Northern Germany.
Methods: A total of 1044 patients who had been operated with sporadic colorectal carcinoma
(median age at diagnosis: 59 years) were recruited and compared to 724 sex-matched, population-
based control individuals (median age: 68 years). Genetic investigation was carried out following
both a coding SNP and haplotype tagging approach. Subgroup analyses for N = 143 patients with
early manifestation of CRC (50 age at diagnosis) were performed for all CARD loci and subgroup
analyses for diverse age strata were carried out for CARD15 mutations R702W, G908R and
L1007fs. In addition, all SNPs were tested for association with disease presentation and family
history of CRC.
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Results: No significant differences were observed between the patient and control allelic or
haplotypic spectra of the three genes under study for the total cohort (N = 1044 patients). None
of the analysed SNPs was significantly associated with either tumour location or yielded significant
association in the familial or non-familial CRC patient subgroups. However, in a patient subgroup
(45 age at diagnosis) with early disease manifestation the mutant allele of CARD15 R702W was
found to be significantly associated with disease susceptibility (9.7% in cases vs 4.6% in controls;
Pallelic = 0.008, Pgenotypic = 0.0008, ORallelic = 2.22 (1.21-4.05) ORressessive = 21.9 (1.96-245.4).
Conclusion: Variation in the innate immunity genes CARD4, CARD8 and CARD15 is unlikely to play
a major role in the susceptibility to CRC in the German population. But, we report a significant
disease contribution of CARD15 for CRC patients with very early disease manifestation, mainly
driven by variant R702W.
Background
Colorectal cancer (CRC) occurs both as a part of recog-
nized heritable syndromes and in the form of "sporadic"
disease. However, epidemiological studies have also
revealed familial clustering of CRC outside the recognized
syndromes [1]. Estimates of the relative familial recur-
rence risk of nonsyndromic CRC range from 1.7 for unse-
lected cases [2] to 6.2 for siblings of index patients aged
<55 years [3]. As yet, the molecular basis of this familial
clustering of "sporadic" CRC has not been fully explored.
Epidemiological and functional evidence suggest that can-
cer may arise in the context of chronic inflammation.
Inflammatory bowel disease (IBD) is a well established
example in that patients with IBD have an increased risk
for the development of CRC [4]. It is estimated that 1-2%
of all CRC cases in general population are due to a com-
plicated course of ulcerative colitis (UC) or Crohn disease
(CD), and up to 15% of all patients with IBD develop
CRC during their life [5,6]. Therefore, it appears sensible
to hypothesize that genetic factors predisposing to, or
involved in, the chronic inflammatory response in IBD
also play an important role for the predisposition to CRC.
As regards CD, the CARD15 (caspase recruitment domain
family, member 15) gene mutations rs2066844 (R702W),
rs2066845 (G908R) and rs2066847 (L1007fs) were origi-
nally shown to be associated with an increase disease risk
[7,8], and this association has since been replicated in
numerous Caucasian populations [9-11]. The CARD15
gene overlaps with the linkage-based IBD1 locus on chro-
mosome 16q12. It exerts its biological function as part of
a larger molecular network of genes involved in innate
immune recognition and regulation [12]. There are two
other genes in this CARD family that have been impli-
cated in the etiology of IBD as well. These include
CARD4/NOD1 [13] and CARD8/TUCAN [14], both of
which also function as intracellular receptors of bacterial
products, but with different ligand specificity.
CARD4/NOD1 is located within a susceptibility locus for
IBD on chromosome 7p14. CARD4 and is an additional
PAMP receptor, that is linked to up apoptosis and acti-
vates NF-B. The complex intronic indel polymorphism
ND1+32656 (partially defined by rs6958571) has
recently been reported to be associated with IBD [13].
CARD8/TUCAN  (tumor-up-regulated CARD-containing
antagonist of caspase nine) is expressed in gastrointestinal
epithelium. There is evidence to suggest that CARD8 may
be a negative regulator of NF-B and also has a regulatory
effect on apoptosis. The common variant
rs2043211(c.30T>A) introduces a stop codon (Cys10Ter)
at position 10 of the amino acid sequence. The common
allele T was recently found to be associated with Crohn
Disease [14].
Recently, several studies implicated CARD15 in the sus-
ceptibility to CRC. Thus, Kurzawski et al. [15] observed an
increased frequency in comparison to newborns of the
3020InsC mutation among 250 Polish CRC patients aged
>50 years at the time of diagnosis resulting in an odds
ratio of 2.2. Interestingly, no evidence for an association
with CRC was found in younger patients. The 3020InsC
association was confirmed in a subsequent study from
Greece [16] and for CARD15 R702W in a study from New
Zealand [17]. However, three subsequent studies from
Finnland [18,19] and Hungary [20] failed to corroborate
any of these findings. A summary of CARD15 allele fre-
quencies observed in different CRC populations is given
in Table 1.
In view of these controversial results, and in order to
obtain a more complete assessment of the impact of vari-
ation in the innate immunity genes on CRC susceptibility,
we investigated multiple variants of the CARD4, CARD8
and CARD15 genes in a large case-control sample from
Northern Germany, following both a haplotype tagging
and a coding SNP approach.B
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Table 1: Summary of association analyses and overview of allele frequencies of CARD15 mutations stratified by age and population.
--------------------------Current study---------------------------
Country,
Ref.
Poland,
[15]
Poland,
[15]
Finnland,
[18]
Germany Germany Germany Germany Germany Greece,
[16]
New 
Zealand,
[17]
Hungary,
[20]
Finnland,
[18]
Age at
diagnosis
>50  50  50  45  50  60 >50 total total total total total
N CRC 250 50 68 72 143 597 901 1044 104 133 194 953
(926*)
N controls 300 300 348 724 724 724 724 724 100 201 200 348
R702W
CRC % Allele 
freq.
/ / / 9.7 7.7 5.4 4.7 5.1 4.8 7.1 1.8 2.2
Controls % Allele 
freq.
/ / / 4.6 4.6 4.6 4.6 4.6 1 3 1.5 2.1
p value / / / 0.008 0.03 0.30 0.83 0.5 0.02 0.03 0.78 0.88
ORAllelic / / / 2.22 1.75 1.2 1.04 1.13 5.21 2.3 1.21 1.04
[95% CI] [1.21--
4.05]
[1.05--
2.91]
[0.85--
1.71]
[0.74--
1.44]
[0.82--
1.55]
[1.11--
24.23]
[1.1--5] [0.39--
3.67]
[0.61 -- 
1.78]
G908R
CRC % Allele 
freq.
/ / / 2.1 2.1 1.4 1.4 1.5 8.65 2.2 1.8 0.3
Controls % Allele 
freq.
/ / / 1.2 1.2 1.2 1.2 1.2 3.5 0.8 1.8 0.2
p value / / / 0.35 0.36 0.57 0.59 0.43 0.025 0.09 0.95 0.57
ORAllelic / / / 1.79 1.69 1.22 1.18 1.27 2.78 3.1 1.03 1.59
[95% CI] [0.52--
6.19]
[0.66--
4.36]
[0.62--
2.39]
[0.64--
2.20]
[0.70--
2.30]
[1.11--
6.98]
[7.7--12.7] [0.35--
3.00]
[0.32 -- 
7.91]
3020InsC
CRC % Allele 
freq.
14.4** 2** 2.2 5.6 3.8 3.9 3.6 3.6 12.5 2.2 3.6 1.9
Controls % Allele 
freq.
7** 7** 1.9 2.8 2.8 2.8 2.8 2.8 6 1 2.5 1.9
p value 0.0046 0.3 0.78 0.06 0.32 0.09 0.21 0.17 0.017 0.19 0.4 0.96
ORAllelic 2.23 0.27 0.78 2.07 1.42 1.44 1.29 1.31 2.44 2.3 1.48 0.98
[95% CI] [1.23--
4.10]
[0.01--
1.97]
[0.17--
3.54]
[0.95--
4.51]
[0.71--
2.83]
[0.94--
2.21]
[0.87--
1.93]
[0.89--
1.93]
[1.15--
5.17]
[0.64--8.4] [0.64--
3.41]
[0.51 -- 
1.88]
* the initial investigation of 3020InsC utilised only 926 CRC cases ** genotype frequencies of carriership of mutant alleleBMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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Methods
Patients and phenotypes
Patients with histologically confirmed colorectal carci-
noma (CRC) were identified through the regional cancer
registry of Schleswig-Holstein or through the records of
surgical departments in Northern Germany. Patients
logged in the registry or patients operated with sporadic
CRC between 2002 and 2005 at hospitals in Kiel, Eckern-
förde, Rendsburg, Schleswig, Flensburg, Husum, Heide,
Niebüll, Neumünster, Itzehoe, Rotenburg, Stade, Rein-
bek, Bad Oldesloh, Detmold, Neustadt, Hamburg-Har-
burg, Hamburg-Altona, Hamburg-Eilbek, Hamburg-
Bergedorf, Hamburg-Barmbek, Bremen and Lüneburg
were contacted by mail and invited for participation in
this study. Patients who did not respond were sent one
written reminder. Individuals who agreed to participate
were contacted through the recruitment office of the POP-
GEN biobank http://www.popgen.de[21]. They were
interviewed by mail questionnaire and a venous EDTA
blood sample was obtained either at the POPGEN office
or by the patient's general practitioner. All study protocols
were approved by the institutional ethics committees and
the local data protection officer. Written informed con-
sent was obtained from all study participants. For both
cases and controls, the study was restricted to probands of
German ancestry, i. e. only individuals whose parents
were born in Germany. Patients and controls fulfilling
either of the clinical Amsterdam or Bethesda criteria for
HNPCC were excluded for the study [22], as were patients
with a history of inflammatory bowel disease (IBD). The
first consecutive 522 male and 522 female participants
were included in the study, yielding a sample size of 1044
patients. The median age at diagnosis was 59 years (range:
18-92 years; Table 2). Patients with FAP (as were all other
known monogenic forms of CRC) were excluded from the
study. Patients having at least 1 first-degree relative diag-
nosed with CRC were defined as familial cases, whereas
non-familial cases had no first-degree relatives with CRC.
Healthy control individuals (N = 724, including 362
males) with a median age at time of recruitment of 68
years (range: 48-81 years) were obtained from the popu-
lation-derived pool of controls individuals in the POP-
GEN project, identified on the basis of the local
population registry [21]. Control individuals with a his-
tory of malignant disease or IBD were excluded from the
study. Controls were sex- and age-matched to the case
sample, with a median age of 10 (± 1) years above the
cases' age at diagnosis.
Genotyping
DNA from all samples was prepared using the FlexiGene
chemistry (Qiagen, Hilden, Germany) according to the
manufactures protocols. DNA samples were evaluated by
gel electrophoresis and adjusted to 20-30 ng/l DNA con-
tent using the Picogreen fluorescent dye (Molecular
Probes - Invitrogen, Carlsbad, Ca, USA). One microliter of
genomic DNA was amplified with the GenomiPhi (Amer-
sham, Uppsala, Sweden) whole genome amplication kit
and fragmented at 99°C for three minutes. One hundred
nanograms of DNA were dryed overnight in TwinTec
hardshell 384 well plates (Eppendorf, Hamburg, Ger-
many) at room temperature. Genotyping was performed
for these plates using the SNPlex chemistry (Applied Bio-
systems, Foster City, USA) on an automated platform with
TECAN Freedom EVO and 384 well TEMO liquid han-
dling robots (TECAN, Männedorf, Switzerland). Geno-
types were reviewed manually using the Genemapper 4.0
(Applied Biosystems) software. None of the variants
showed a significant departure from Hardy-Weinberg
equilibrium (p > 0.1), indicating robust genotyping in
this experiment. All process data were logged and admin-
istered with a database-driven LIMS [23].
Table 2: Overview and clinicopathologic characteristics of the cohorts and subgroups used in the present study.
Sample N Median age Median age at diagnosis %male
Cases (total cohort) 1044 63 59 50%
Tumour location
Colon (Subgroup 1) 539 63 59 47%
Rectum (Subgroup 2) 469 63 59 53%
Rectum and remaining colon 36 64 59 50%
Family history
Familial CRC (Subgroup 3) 189 64 60 45%
Non-Familial CRC (Subgroup 4) 855 63 59 51%
Cases (age at diagnosis  60) 337 60 56 50%
Cases (age at diagnosis  50) 143 49 45 43%
Cases (age at diagnosis  45) 72 45 41 42%
Cases (age at diagnosis > 50) 901 64 60 50%
Controls (sexmatched to the total cohort) 724 68 / 50%
Controls (sexmatched to case  50) 639 68 / 43%
Subcohorts 1-4 were not significantly different in respect to tumor location and family history to the total CRC patient cohort.BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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Genotypes of nonsynonymous polymorphism R702W
(rs2066844) and the complex intronic indel polymor-
phism ND1+32656 (PCR forward primer GTCCTTCT-
GGTGTACTGATGT ATGAAA, PCR reverse primer,
Taqman probe VIC (T-allele): CGCCCCCCACACA, Taq-
man probe FAM [GG-allele): CCCCCCCCCACAC) were
determined using the TaqMan (Applied Biosystems) sys-
tem. Reactions were completed and read in a 7900 HT
TaqMan sequence detector system (Applied Biosystems).
The amplification reaction was carried out with the Taq-
Man universal master mix. Thermal cycling conditions
consisted of 1 cycle for 10 minutes at 95°C, 45 cycles for
15 seconds at 95°C, and 45 cycles for 1 minute at 60°C.
Primers and probes have been reported before [24].
SNP selection and data analysis
For all genes, single nucleotide polymorphism (SNPs)
were retrieved from HAPMAP http://www.hapmap.org by
the automated selection, from the CEU dataset, of haplo-
type tagging SNPs for Causcasians (setting: Mendel errors:
0, minor allele frequency >0.05, HWE cut-off p > 0.01)
[25]. In addition, coding SNPs reported in dbSNP or in
the literature were included if they had a a minor allel fre-
quency 0.01 in Caucasians. Figures 1, 2 and 3 show the
distribution of markers across genes and the regional hap-
lotype structures as generated by HAPLOVIEW.
The study was of case-control design. In order to improve
power - i. e. to detect association to variants on the haplo-
types, that are not directly tagged by one of the SNPs in the
experiments - a sliding window haplotype analysis using
window sizes of two to five markers was performed. Hap-
lotype analysis was performed using COCAPHASE
through the UNPHASED suite of programs http://
www.rfcgr.mrc.ac.uk/~fdudbrid/software/unphased/[26].
COCAPHASE performs likelihood ratio tests under a log-
linear model of the probability that a haplotype belongs
to the case rather than to the control group. The expecta-
tion maximization (EM) algorithm is utilized to resolve
uncertain haplotypes and provides maximum-likelihood
estimates of frequencies. One single overall test statistic
per sliding window (HAP2-5) is reported as a global sig-
nificance value P for each haplotype tested. Nominal p
values will be reported fo all tests. Single-point genotype-
and allele-based tests of association were performed using
a chi-squared test or fisher exact test.
Overview of the physical and genetic structure of the CARD4 gene region Figure 1
Overview of the physical and genetic structure of the CARD4 gene region. The gene is annotated on the genomic 
minus strand. The physical position of the investigated SNPs and a schematic illustration of the gene structure are shown in the 
top panel. The coordinates refer to genome assembly build 35. The lower panel gives an overview of the linkage disequilibrium 
structure of the locus [D'] as generated by Haploview [29]. The LD plots have been generated from the HAPMAP data.BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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Results
A systematic power analysis was performed for the 1044
cases and 724 controls available for study, adopting vari-
ous allelic odds ratio between 1 and 2, a nominal signifi-
cance level of 0.05, and minor allele frequencies of 0.1,
0.2, 0.3, 0.4 and 0.5 for a potential susceptibility muta-
tion, respectively [27]. The power to detect odds ratios
>1.5 was found to be >80% under all models (Figure 4).
For frequent susceptibility factors, even odds ratios >1.3
would be detectable with the same power.
All tagging SNPs (see Methods section) from the three
candidate genes and all validated nonsynonymous SNPs
with a minor allele frequency 1% in Caucasians were
included in the genotyping. Sixteen SNPs in the CARD4
gene, 13 SNPs in the CARD8, and 8 SNPs in the CARD15
gene were selected. These markers provided a good cover-
age of the respective genes and tagged all major haplotype
blocks as determined by the tagging routine [28] imple-
mented in HAPLOVIEW [29]. The disease association
analyses were performed in single-tier fashion, using all
cases and controls. Because earlier reports have indicated
age-stratification of CARD15  association and younger
patients in general may have a stronger genetic compo-
nent to their disease, a separate analysis including only
cases with an age of onset below 50 (median age of onset
45) compared to a sexmatched control population was
performed, too. In addition, a further subgroup analysis
for cases with an age of onset below 45 (median age of
onset 41) was performed for CARD15 risk variants, too.
CARD4
For CARD4, some 16 SNP markers were genotyped. Figure
1 provides an overview of the linkage disequilibrium pat-
tern generated from Hapmap Caucasian samples and the
location of the tag SNPs in the gene. Association findings
are summarised in Table 3. Nominal p-values for allelic
association tests in the total cohort ranged from 0.10 to
0.92; sliding window haplotype analyses of two to five
markers yielded p values between 0.08 and 0.99, respec-
tively. The complex intronic indel polymorphism
ND1+32656 yielded a p-value of 0.13 for the total cohort.
ND1+32656 is part of a conserved haplotype also defined
by SNPs rs2907748 and rs2907749 [30]. Both SNPs
rs2907748 and rs2907749 (31 bp downstream to
rs6958571) were also included in our experiments for
ease and robustness of genotyping [30] and yielded simi-
lar p-values as ND1+32656. The non-synonymous coding
SNP E266K, which was reported to be associated with dis-
ease susceptibility for Crohn's disease [31] in Hungarian
Overview of the physical and genetic structure of the gene CARD8 gene region Figure 2
Overview of the physical and genetic structure of the gene CARD8 gene region. The gene is annotated on the 
genomic minus strand. For details, see legend to Figure 1.BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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patients, yielded a p-value of 0.36 for the total cohort. In
the analysis of the total patient sample, none of the single
point or haplotype analyses revealed any significant asso-
ciation with CRC risk.
The subgroup analysis of patients younger than 50 years
at onset of disease for ND1+32656 yielded an allelic p-
value of 0.06 (Table 2). The subgroup analysis of the most
youngest CRC patients (N = 72; 45 age at diagnosis)
yielded (Pallelic = 0.06, Pgenotypic = 0.025, ORallelic = 1.29
(0.79-2.11) and did not improve the results. For E266K a
significant association was observed in patients younger
than 50 years (Pallelic = 0.004, ORallelic = 0.62 (0.45-0.86).
A similarly p-value of 0.003 was yielded for the intronic
tag SNP rs2075819 that is in strong LD (r2 = 0.9) to
E266K. The subgroup analysis of the most youngest CRC
patients (<45) for E266K yielded (Pallelic = 0.03, Pgenotypic =
0.014, ORallelic = 0.48 (0.28-0.82)). However, both E266K
Overview of the physical and genetic structure of the gene CARD15 gene region Figure 3
Overview of the physical and genetic structure of the gene CARD15 gene region: The gene is annotated on the 
genomic plus strand. For details, see legend to Figure 1.
Power analysis of the sample used in the present study Figure 4
Power analysis of the sample used in the present study. The power of an allelic test is plotted as a function of the 
underlying odds ration of the tested genetic variant. Calculations were performed for a nominal significance level of 0.05 in a 
two-sided test. The different colors denote the frequency of the minor allele of the respective variant. Clearly, power 
increased for frequent variants and higher underlying odds. It is evident, that odds ratios above 1.6 should be detectable with a 
power greater 80% for all allele frequencies. The graph was generated using PS-power [27] and shows the power as a function 
of the odds ratio (x-axis).BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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and rs2075819 only have borderline significance in
respect to a significance threshold of p 0.003 after Bonfer-
roni correction for multiple testing (N = 16 SNP marker).
CARD8
In total, 13 SNPs in the CARD8 gene were genotyped (Fig-
ure 2). In our study, neither allele of rs2043211 was asso-
ciated with CRC (Pallelic = 0.86 ORallelic = 1.01 (0.88-1.17).
Variant rs11881179 (c.202A>G) is a coding SNP that
leads to the substitution of valin by isoleucin at position
68 of the amino acid sequence. No difference in terms of
the minor allele frequency (MAF) was observed between
cases and controls (MAF:c.202Gcases = 0.1%, c.202Gcontrols
= 0.1%, Pallelic = 0.965). The Caucasians allele frequencies
in HAPMAP and the observed allele counts in our control
group (Table 4) were very similar (p > 0.2), thereby justi-
fying the use of HAPMAP for the selection of tagging
SNPs. All remaining single point allelic and genotypic
association tests resulted in nominal p-values between
0.09 and 0.99. Haplotype analysis yielded the lowest p
value of 0.23 for a 3-locus haplotype spanning from
rs10500300 to rs10405717.
The subgroup analysis of younger patients (50 age at
diagnosis) for rs2043211 yielded a similar allelic p-value
of 0.23 (Table 4). The intronic SNP rs11670259 was sig-
nificantly associated with CRC (Pallelic = 0.004, ORallelic =
1.46 (1.13-1.90), but remains only borderline significant
in respect to a significance threshold of p 0.004 after Bon-
ferroni correction for multiple testing (N = 13 SNP
Table 3: Results of the association analyses of tagging SNPs in the CARD4 gene.
dbSNP id CARD4
Position
MAF
case
MAF
cont
ORallelic[CI95%]P allelic PHAP2 PHAP3 PHAP4 PHAP5
1044 CRC patients vs 724 sex-matched control individuals
Rs5743369 intron 0.15 0.16 0.93 [0.78-1.12] 0.445 0.371 0.252 0.333 0.421
Rs10267377 intron 0.30 0.28 1.09 [0.94-1.27] 0.253 0.222 0.322 0.556 0.274
Rs2907748 intron 0.26 0.23 1.14 [0.98-1.34] 0.103 0.415 0.748 0.637 0.546
ND1+32656 intron 0.26 0.24 1.13 [0.96-1.32] 0.131 0.512 0.405 0.238 0.148
Rs2907749 intron 0.29 0.27 1.1 [0.95-1.28] 0.234 0.365 0.095 0.112 0.199
Rs2284358 intron 0.29 0.27 1.09 [0.94-1.26] 0.304 0.618 0.152 0.204 0.184
Rs2075820 E266K 0.25 0.27 0.93 [0.80-1.09] 0.363 0.666 0.367 0.374 0.294
Rs7789045 intron 0.46 0.47 0.96 [0.84-1.10] 0.558 0.755 0.366 0.35 0.384
rs2075819 intron 0.27 0.29 0.92 [0.79-1.07] 0.307 0.092 0.086 0.22 0.343
rs3823773 intron 0.12 0.12 0.98 [0.79-1.21] 0.891 0.984 0.986 0.864 0.382
rs736781 intron 0.19 0.19 0.99 [0.83-1.17] 0.919 0.941 0.765 0.283 0.352
rs2893375 intron 0.17 0.17 1.03 [0.86-1.23] 0.783 0.911 0.162 0.255 0.172
rs2529440 intron 0.42 0.42 1.02 [0.89-1.17] 0.777 0.364 0.243 0.175 -#
rs4720004 intron 0.15 0.14 1.13 [0.93-1.37] 0.236 0.525 0.327 -# -#
rs932272 intron 0.40 0.39 1.04 [0.91-1.20] 0.536 0.286 -# -# -#
rs17770244 intron 0.06 0.06 1.01 [0.76-1.35] 0.927 -# -# -# -#
143 CRC patients (age at diagnosis  50) vs 639 sex-matched control individuals
rs5743369 intron 0.12 0.16 0.7 [0.47-1.03] 0.065 0.069 0.09 0.19 0.22
rs10267377 intron 0.34 0.29 1.26 [0.96-1.66] 0.093 0.212 0.41 0.55 0.36
rs2907748 intron 0.28 0.23 1.3 [0.97-1.74] 0.075 0.273 0.52 0.32 0.15
ND1+32656 intron 0.29 0.24 1.31 [0.98-1.76] 0.065 0.263 0.13 0.04 0.10
rs2907749 intron 0.32 0.27 1.25 [0.95-1.66] 0.111 0.06 0.007 0.04 0.10
rs2284358 intron 0.32 0.28 1.25 [0.95-1.65] 0.117 0.01 0.02 0.06 0.07
rs2075820 E266K 0.19 0.27 0.62 [0.45-0.86] 0.004a 0.009 0.03 0.04 0.06
rs7789045 intron 0.43 0.47 0.84 [0.65-1.09] 0.188 0.01 0.01 0.04 0.06
rs2075819 intron 0.21 0.29 0.62 [0.46-0.85] 0.003a 0.005 0.01 0.02 0.04
rs3823773 intron 0.09 0.12 0.69 [0.44-1.07] 0.098 0.07 0.08 0.11 0.03
rs736781 intron 0.14 0.2 0.66 [0.46-0.95] 0.025a 0.03 0.05 0.01 0.02
rs2893375 intron 0.21 0.17 1.3 [0.94-1.79] 0.110 0.07 0.01 0.03 0.02
rs2529440 intron 0.41 0.42 0.96 [0.74-1.24] 0.750 0.01 0.03 0.02 -#
rs4720004 intron 0.19 0.14 1.5 [1.07-2.09] 0.017a 0.03 0.03 -# -#
rs932272 intron 0.39 0.39 0.98 [0.75-1.28] 0.887 0.76 -# -# -#
rs17770244 intron 0.06 0.06 1.11 [0.65-1.89] 0.704 -# -# -# -#
a P value were not significant after Bonferroni correction for multiple testing, *no odds ratio calculated owing to low allele frequency, # p value 
reported for the first marker in the haplotype. The minor allele frequencies (MAF) for cases and controls are reported. P values and odds ratios are 
reported for the allelic (pallelic) test. Columns PHAP2 to PHAP5 refer to a sliding window haplotype analysis using COCAPHASE. For example, PHAP3 
(0.252) for rs5743369 reports the global significance value for the window 3 haplotype spanning rs5743369- rs10267377- rs2907748.BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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marker). None of the other single marker or haplotyp
SNPs at that locus yielded significant p values after Bon-
ferroni correction was applied.
CARD15
Eight SNP markers in the CARD15 gene were genotyped
(Figure 3) and the results of the respective association
analyses are summarised in Table 1, 5, 6 &7. The haplo-
type structure and the risk alleles at CARD15  are well
defined [32], so that the initial analyses focussed on the
three main coding SNPs (Table 5). No association was
seen between CRC and CARD15 variants R702W (5.1% in
cases vs 4.6% in controls; Pallelic = 0.50, Pgenotypic = 0.59),
G908R (1.5% vs 1.2%; Pallelic = 0.43, Pgenotypic = 0.60) and
L1007fs (3.6% vs 2.8%; Pallelic = 0.17, Pgenotypic = 0.36).
Two compound heterozygotes carrying R702W and
G908R and four compound heterozygotes carrying
R702W and L1007fs were observed among the CRC
patients, whereas non of these combinations was found in
controls. The combined frequency of genotypes harbour-
ing R702W, G908R or L1007fs was also not significantly
different in cases and controls (10.2% vs 8.6%; Pallelic =
0.10, Pgenotypic = 0.10).
Although the haplotype structure of CARD15 has been
explored before, we performed a sliding window haplo-
type analysis of this locus for the sake of consistency. The
results reflected the pattern seen in the coding SNP analy-
sis (Table 5) and were essentially negative: Only a nomi-
nal significance level of 0.04 was obtained for the 2-locus
haplotype spanning rs5743291 and rs2066847. None of
the neighbouring haplotypes showed any evidence for an
association with CRC.
The analysis of the younger patient groups in contrast
yielded a significant association of CARD15  R702W
(rs2066844) with CRC (7.7% in cases vs 4.6% in controls;
Pallelic = 0.029, Pgenotypic = 0.033, ORallelic = 1.75 (1.05-
2.91), ORressessive = 9.46 (0.85-105.2). The association was
even more pronounced when the most youngest CRC
Table 4: Results of the genetic association analyses of the tagging SNPs in the CARD8 gene.
dbSNP id CARD8
Position
MAF
case
MAF
cont
ORallelic[CI95%]P allelic PHAP2 PHAP3 PHAP4 PHAP5
1044 CRC patients vs 724 sex-matched control individuals
rs4802445 3'UTR 0.44 0.45 0.95 [0.83-1.08] 0.431 0.549 0.540 0.615 0.305
rs1966625 intron 0.09 0.10 0.90 [0.72-1.13] 0.360 0.552 0.463 0.368 0.726
rs16981829 intron 0.33 0.33 1.00 [0.86-1.15] 0.976 0.998 0.419 0.712 0.697
rs11881179 V68I 0.001 0.001 1.04 [0.17-6.25] 0.964 0.975 0.999 0.971 0.518
rs4802449 intron 0.34 0.34 0.99 [0.86-1.14] 0.856 0.966 0.828 0.406 0.488
rs2043211 C10Ter 0.32 0.32 1.01 [0.88-1.17] 0.857 0.907 0.474 0.477 0.549
rs6509364 intron 0.34 0.34 1.02 [0.88-1.17] 0.820 0.593 0.642 0.661 0.602
rs11670259 intron 0.35 0.34 1.05 [0.91-1.21] 0.486 0.483 0.592 0.675 0.517
rs12984929 intron 0.41 0.39 1.09 [0.95-1.25] 0.235 0.545 0.760 0.343 0.417
rs11672725 intron 0.20 0.19 1.02 [0.86-1.21] 0.819 0.819 0.865 0.350 -#
rs10500300 intron 0.08 0.08 1.06 [0.83-1.36] 0.619 0.820 0.226 -# -#
rs6509368 intron 0.44 0.44 1.02 [0.89-1.16] 0.816 0.544 -# -# -#
rs10405717 intron 0.15 0.17 0.90 [0.75-1.07] 0.238 -# -# -# -#
143 CRC patients (age at diagnosis 50) vs 639 sex-matched control individuals
rs4802445 3'UTR 0.4 0.45 0.81 [0.62-1.05] 0.106 0.197 0.310 0.352 0.321
rs1966625 intron 0.07 0.1 0.73 [0.45-1.18] 0.200 0.322 0.373 0.388 0.692
rs16981829 intron 0.31 0.33 0.94 [0.71-1.24] 0.663 0.603 0.388 0.647 0.729
rs11881179 V68I 0 0.002 N/A* 0.503 0.166 0.280 0.372 0.039
rs4802449 intron 0.39 0.34 1.25 [0.96-1.63] 0.100 0.232 0.341 0.028 0.131
rs2043211 C10Ter 0.29 0.32 0.84 [0.63-1.11] 0.225 0.251 0.024 0.144 0.067
rs6509364 intron 0.32 0.33 0.94 [0.72-1.24] 0.668 0.004 0.031 0.020 0.092
rs11670259 intron 0.43 0.34 1.46 [1.13-1.90] 0.004a 0.023 0.018 0.118 0.159
rs12984929 intron 0.37 0.39 0.93 [0.71-1.21] 0.595 0.865 0.441 0.332 0.407
rs11672725 intron 0.2 0.2 1.04 [0.75-1.43] 0.830 0.755 0.575 0.615 -#
rs10500300 intron 0.09 0.08 1.14 [0.72-1.80] 0.583 0.590 0.750 -# -#
rs6509368 intron 0.47 0.44 1.1 [0.85-1.42] 0.479 0.585 -# -# -#
rs10405717 intron 0.17 0.16 1.08 [0.77-1.52] 0.648 -# -# -# -#
a P value were not significant after Bonferroni correction for multiple testing, *no odds ratio calculated due to low allele frequency, # p-value is 
reported for the first marker in the haplotype window. The minor allele frequencies (MAF) for cases and controls are reported. P values and odds 
ratios are reported for the allelic (pallelic) test. Columns PHAP2 to PHAP5 refer to a sliding window haplotype analysis using COCAPHASE. For 
example, PHAP5 (0.417) for rs12984929 reports the global significance value for the window 5 haplotype spanning rs12984929-rs11672725- 
rs10500300- rs6509368- rs10405717.BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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patients (45 age at diagnosis) were analysed (9.7% in
cases vs 4.6% in controls; Pallelic = 0.008, Pgenotypic = 0.0008,
ORallelic = 2.22 (1.21-4.05), ORressessive = 21.9 (1.96-245.4).
The p value yielded for the genotypic association remains
significant after Bonferroni correction. G908R and
L1007fs were not found to be significantly associated with
CRC in any of the analysed age groups.
The combined frequency of genotypes harbouring
R702W, G908R or L1007fs were significantly higher in
patient than controls for the youngest CRC patient group
(45 age at diagnosis) (16.7% in cases vs 8.6% in controls;
Pallelic = 0.0014, Pgenotypic = 0.0021, ORressessive = 12.1 (2.37-
61.36), both p-values remained significant after Bonfer-
roni correction. When compound heterozygotes were
classified as being equal to homozygotes of the mutant
allele for R702W (Pgenotypic = 0.000013, ORcarriership = 1.99
(1.02-3.89), ORressessive = 32.9 (3.36-321.2) was yielded
and for combined frequency of genotypes harbouring
R702W, G908R or L1007fs R702W (Pgenotypic = 0.0001,
ORcarriership = 2.19 (1.28-3.75), ORressessive = 12.1 (2.37-
61.31), respectively (Table 6).
In contrast, R702W was not significant in the more older
patient group (N = 901, >50 age at diagnosis), (4.7% in
cases vs 4.6% in controls; Pallelic = 0.83) (Table 1). Similar
negative results for R702W were obtained when patients
diagnosed with CRC before age 60 (N = 597) were ana-
lysed (5.4% in cases vs 4.6% in controls; Pallelic = 0.3).
Stratification analysis of disease presentation and family 
history
None of the analysed SNPs for CARD4, 8 and 15 was sig-
nificantly associated (all p values > 0.05; Table 7) with
tumour location or yielded significant association in the
familial or non-familial CRC patient subgroups (Table 7
only lists a small selection of the analysed SNPs).
Discussion
The functional relationship between inflammation and
cancer is well established and dates back to Virchow in
1863. He propagated this interesting hypothesis based on
the observation that some classes of irritants, together
with the tissue injury and causative inflammation,
enhance cell proliferation. By now it is known that many
cancers arise from sites of infection, chronic irritation and
inflammation. About 15% of the global cancer burden is
attributable to infectious agents, and inflammation is a
major element of these chronic infections. For example,
the development of mucosal associated lymphoid tissue
(MALT) B cell lymphoma and gastric cancer is associated
with Helicobacter pylori-induced chronic gastritis, and an
increased risk of CRC accompanies inflammatory bowel
disease (IBD) [4,33-35]. Therefore, we tried to replicate
previously reported associations of functional SNPs in
innate immunity gene CARD15 with CRC susceptibility,
and also investigated variants of the CARD4 and CARD8
innate immune genes in this context.
Table 5: Results of the genetic association analyses of the tagging SNPs in the CARD15 gene.
dbSNP id CARD15 Position MAF
case
MAF
cont
ORallelic[CI95%]P allelic PHAP2 PHAP3 PHAP4 PHAP5
1044 CRC patients vs 724 sex-matched control individuals
rs5743266 5'UTR 0.30 0.29 1.05 [0.91-1.22] 0.459 0.687 0.236 0.362 0.517
rs13339578 intron 0.30 0.30 0.99 [0.86-1.15] 0.980 0.835 0.903 0.443 0.209
rs2066844 R702W 0.05 0.05 1.13 [0.82-1.55] 0.501 0.838 0.391 0.323 0.317
rs2066845 G908R 0.01 0.01 1.27 [0.70-2.30] 0.432 0.353 0.269 0.266 0.169
rs5743289 intron 0.18 0.17 1.11 [0.93-1.33] 0.247 0.103 0.151 0.132 -#
rs5743291 I955V 0.08 0.10 0.80 [0.64-1.01] 0.052 0.041 0.121 -# -#
rs2066847 L1007fs 0.04 0.03 1.31 [0.89-1.93] 0.171 0.295 -# -# -#
rs8056611 3'flank. region 0.49 0.49 1.02 [0.89-1.17] 0.823 -# -# -# -#
143 CRC patients (age at diagnosis 50) vs 639 sex-matched control individuals
rs5743266 5'UTR 0.31 0.29 1.11 [0.84-1.47] 0.456 0.232 0.196 0.232 0.323
rs13339578 intron 0.32 0.3 1.09 [0.83-1.44] 0.521 0.070 0.145 0.106 0.153
rs2066844 R702W 0.08 0.05 1.75 [1.05-2.91] 0.029a 0.03 0.117 0.210 0.228
rs2066845 G908R 0.02 0.01 1.69 [0.66-4.36] 0.273 0.161 0.305 0.275 0.281
rs5743289 intron 0.21 0.17 1.29 [0.94-1.78] 0.118 0.323 0.185 0.183 -#
rs5743291 I955V 0.08 0.1 0.74 [0.46-1.19] 0.214 0.116 0.598 -# -#
rs2066847 L1007fs 0.04 0.03 1.42 [0.71-2.83] 0.316 0.613 -# -# -#
rs8056611 3'flank. region 0.5 0.48 1.05 [0.81-1.36] 0.692 -# -# -# -#
a P value were not significant after Bonferroni correction for multiple testing, *no odds ratio calculated due to low allele frequency, # p-value 
reported for the first marker in the haplotype window. The minor allele frequencies (MAF) for cases and controls are reported. P values and odds 
ratios are reported for the allelic (pallelic) test. Columns PHAP2 to PHAP5 refer to a sliding window haplotype analysis using COCAPHASE. For 
example, PHAP2 (0.295) for rs2066847 reports the global significance value for the window 2 haplotype sapnning rs2066847- rs8056611.BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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Table 6: Genotype and allele frequencies for CARD15 mutations among German CRC patients and controls.
CARD15 N 1*1 1*2 2*2 1*2 (c) 2*2 (c) R702W-
G908R
R702W 
- 1007fs
Pallelic Pgeno Pgeno(c)
a
ORCAR
(c)
[CI95%]a
ORREC
(c)
[CI95%]a
R702W 4 5 C R C 7 26 01 0 29 3 0 1 0 . 0 0 8 b 0.0008b 1.3 • 10-5 
b
1.99 
[1.02-
3.89]b
32.9 
[3.36-
321.2]b
50CRC 143 123 18 2 17 3 0 1 0.029 0.033 0.0062 1.66 
[0.96-
2.86]
14.2 
[1.46-
137.6]
Control 639 582 56 1 56 1
CRC 1044 941 99 4 93 10 2 4 0.501 0.591 0.098 1.09 
[0.78-
1.51]
6.2 [0.79-
48.4]
Control 724 658 65 1 65 1
G908R 45CRC 72 69 3 0 69 0 0.350b n/a n/a 1.81 
[0.51-
6.32]b
N/A
50CRC 143 137 6 0 137 0 0.272 n/a n/a 1.71 
[0.65-
4.43]
N/A
Control 639 623 16 0 623 0
CRC 1044 1014 29 1 27 3 2 0 0.432 0.603 0.335 1.23 
[067-
2.24]
N/A
Control 724 707 17 0 707 0
L1007fs 4 5 C R C 7 26 4807 1 0 1 0 . 0 6 2 b 0.086b 0.077b 2.25 
[1.00-
5.04]b
N/A
50CRC 143 132 11 0 10 1 0 1 0.316 0.319 0.459 1.53 
[0.75-
3.01]
N/A
Control 639 606 31 2 31 2
CRC 1044 972 69 3 65 7 0 4 0.171 0.358 0.272 1.33 
[0.89-
2.00]
1.1 [0.17-
6.35]
Control 724 686 36 2 686 2
R702W/
G908R/
L1007fs
4 5 C R C 7 25 02 0 21 9 3 0 1 0 . 0 0 1 b 0.002b 0.0001b 2.19 
[1.28-
3.75]b
12.1 
[2.37-
61.31]b
50CRC 143 107 34 2 33 3 0 1 0.013 0.038 0.015 1.69 
[1.09-
2.60]
4.9 [0.99-
25.01]
Control 639 533 103 3 103 3BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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The international HAPMAP project http://www.hap
map.org has generated a whealth of genotype and marker
information that significantly facilitates the design of can-
didate gene studies [25]. For our candidate gene study, a
primary haplotype tagging approach was chosen, i.e. the
genetic variation at both loci was captured by a set of care-
fully selected SNPs. This tagging approach is able to detect
signals from hitherto unknown regulatory or functional
elements in a given genetic region [28,36,37]. Therefore,
it offers potential advantages over a direct mutation screen
of the coding region of a gene because disease susceptibil-
ity may also be conferred by variations, for instance, in
splice sites or intronic enhancers [38,39]. Tagging SNPs
were thus selected from the public HAPMAP http://
www.hapmap.org resources. The genotype and allele fre-
quencies for the SNPs investigated in our control popula-
tion were not significantly different from those of the
Caucasian HAPMAP individuals (Tables 3, 4 and 5),
thereby justifying the selection of tag SNPs from this
resource [25].
We utilized over 1000 patients who have been operated
for CRC, which renders our study the largest case-control
study of CARD15 mutations reported so far. In Germany,
the population median age of affection by CRC is about
69 years for males and 74 years for females [40]. The
CRC 1044 845 191 8 185 14 2 4 0.175 0.347 0.099 1.17 
[0.91-
1.50]
3.3 [0.95-
11.63]
Control 724 603 118 3 118 3
1*1 homozygous wild-type, 1*2 heterozygous, 2*2 homozygous mutant, (c) homozygous for mutant allele and compound heterozygous combined; 
Pallelic and Pgeno are calculated from the observed genotypes (1*1, 1*2, 2*2);a Pgeno 2*2 (c): genotypic p values and ORCAR(c): odds ratio for carriership of 
rare allele and ORREC(c): odds ratio for homozygosity of rare allele under the ressesive disease model were calculated by judging compound heterozygotes 
as homozygotes of the rare allele, Pallelic and Pgeno were calculated without considering compound heterozygotes; bP values and odds ratios for young 
CRC (45 age at diagnosis) were calculated against the total control cohort.
Table 6: Genotype and allele frequencies for CARD15 mutations among German CRC patients and controls. (Continued)
Table 7: Results of the genetic association analyses for subgroups stratified by disease presentation and family history of disease.
Subgroups Gene/Variant N CRC N CON minAFca minAFco P allelic OR allelic
CARD4
Colon (Subgroup 1) ND1+32656 526 720 0.253 0.236 0.336 1.09 [0.91-1.32]
Rectum (Subgroup 2) ND1+32656 459 720 0.265 0.236 0.117 1.16 [0.96-1.41]
Familial (Subgroup 3) ND1+32656 187 720 0.283 0.236 0.058 1.28 [0.99-1.65]
Non-Familial (Subgroup 4) ND1+32656 832 720 0.253 0.236 0.276 1.10 [0.93-1.29]
Colon (Subgroup 1) E266K 535 709 0.252 0.267 0.423 0.93 [0.77-1.11]
Rectum (Subgroup 2) E266K 469 709 0.252 0.267 0.418 0.92 [0.77-1.12]
Familial (Subgroup 3) E266K 188 709 0.247 0.267 0.451 0.90 [0.70-1.18]
Non-Familial (Subgroup 4) E266K 852 709 0.254 0.267 0.429 0.94 [0.80-1.10]
CARD8
Colon (Subgroup 1) C10Ter 468 722 0.312 0.321 0.632 1.05 [0.89-1.24]
Rectum (Subgroup 2) C10Ter 537 722 0.332 0.321 0.558 0.96 [0.80-1.14]
Familial (Subgroup 3) C10Ter 189 722 0.317 0.321 0.886 0.98 [0.77-1.25]
Non-Familial (Subgroup 4) C10Ter 852 722 0.326 0.321 0.794 1.02 [0.88-1.19]
CARD15
Colon (Subgroup 1) R702W 539 723 0.048 0.046 0.760 1.06 [0.73-1.54]
Rectum (Subgroup 2) R702W 469 723 0.055 0.046 0.283 1.23 [0.85-1.78]
Familial (Subgroup 3) R702W 189 723 0.029 0.046 0.155 0.63 [0.33-1.20]
Non-Familial (Subgroup 4) R702W 855 723 0.056 0.046 0.183 1.24 [0.90-1.72]
Colon (Subgroup 1) G908R 539 723 0.017 0.012 0.293 1.43 [0.73-2.79]
Rectum (Subgroup 2) G908R 469 723 0.014 0.012 0.650 1.18 [0.57-2.45]
Familial (Subgroup 3) G908R 189 723 0.019 0.012 0.305 1.59 [0.65-3.86]
Sporadic (Subgroup 4) G908R 855 723 0.014 0.012 0.570 1.20 [0.64-2.24]
Colon (Subgroup 1) L1007fs 539 724 0.040 0.028 0.088 1.46 [0.94-2.26]
Rectum (Subgroup 2) L1007fs 469 724 0.032 0.028 0.542 1.16 [0.72-1.88]
Familial (Subgroup 3) L1007fs 189 724 0.042 0.028 0.141 1.55 [0.86-2.81]
Sporadic (Subgroup 4) L1007fs 855 724 0.035 0.028 0.273 1.26 [0.84-1.89]BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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actual median age of onset in our cases was 59 years. In an
additional attempt to increase the power of our investiga-
tions, only IBD-negative and cancer-free control individu-
als with a moderately higher median age of 68 years were
used. Many polygenic disorders are characterized by a
strong correlation between the age of onset of relatives, as
has been documented for instance in breast cancer [41]
and Alzheimer disease [42]. It is indeed plausible that the
genetic influence upon the development of these disor-
ders is partly reflected by the age at which individuals
develop the disorder [43]. Confounding by population
affiliation was minimized by the restriction to patients of
German ancestry as determined by the birth place of both
parents.
The sample size used in this study has a power >80% for
the detection of allelic odds ratios >1.5 at a significance
level of 0.05 (Figure 4). For more frequent mutation vari-
ants, even odds ratios as small as 1.3 would have been
detected with the same power.
This notwithstanding, none of the single point nominal p
values in any of the tests in the total cohort (N = 1044
CRC patients) were found to be <0.05. Thus, in contrast to
Kurzawski et al. (2004) [15], Papaconstantinou et al.
(2005) [16] and Roberts et al. (2006) [17], we found no
evidence for an association between CARD15 variants and
CRC susceptibility based on the findings of the total
cohort.
However, in patient subgroups of early disease manifesta-
tion (45 and 50 age at diagnosis) we detected a signifi-
cant association of the R702W mutation with CRC. In the
German cohort, this association would have remained
undiscovered if the subgroup analyses for earlier disease
manifestation would had been confined only to patients
with 60 years at diagnosis, as done in previous studies
that did not detect an association with CRC [18-20]. In
line with this, the association signal for all tested CARD15
mutations totally fainted when CRC patients older than
50 years at diagnosis were analysed. No association was
found for G908R. We observed an increase in the fre-
quency of R702W and also 3020insC risk alleles and com-
pound heterozygotes between both with decreasing age of
diagnosis in non-IBD affected CRC patients. Thus,
CARD15 mediated CRC disease susceptibility seems to be
confined to early onset CRC in the German population.
CARD15 R702W and 3020insC affect the C-terminal LRR-
part of NOD2 lead to a reduced responsiveness to bacte-
rial components and are assumed to influence the cross-
talk with Toll-like receptor function that results in a
proinflammatory cytokine bias [44-46]. The resulting
chronic imflammatory state of the colon could provide
the mechanistic link to cancer development.
In the whole, however, our findings corroborate the two
studies from Finnland and Hungary. Both studies dis-
proved CARD15 mutations as major contributors to gen-
eral 'sporadic' colorectal cancer disease susceptibility. In
addition, none of the analysed SNPs was significantly
associated with either tumour location or yielded signifi-
cant association in the familial or non-familial CRC
patient subgroups.
Furthermore, our study did not unravel any major contri-
bution of CARD4 and CARD8 variants to the predisposi-
tion to CRC despite the results of recent genome-wide
association studies [47-54] showing that part of the CRC
risk is due to common low-risk variants. The intronic
complex indel polymorphism CARD4 ND1+ 32656 was
not significantly disease associated neither in the total
cohort nor in the subgroup analysis of younger CRC
patients. The coding polymorphism CARD4 E266K was
reported to be associated with Crohn's disease in Hungar-
ian population with the risk allele being more frequent in
patients than in controls [31]. In contrast, we observed the
E266K mutant allele 8% less frequently in the younger
subgroup of CRC cases (50 age at diagnosis) compared
to controls. Interestingly, in a Scottish IBD population the
mutant allele was likewise observed less frequently,
though not significant, in early onset IBD (<17 age)
patients compared to controls [55].
There may be many explanations of the lack of significant
results for the total CRC cohort in the present study. A
major reason might be population genetic differences in
terms of allele frequencies and in terms of the contribu-
tion of individual risk variants. Regional heterogeneity
within Europe as reported with respect to the contribution
of CARD15 variants to CD susceptibility [32,55] may also
apply to the CRC risk. In addition, environmental factors
may differ widely even between Caucasian populations.
Another critical point may be the necessity of a sufficient
sample size utilized in association studies. There might be
a weakness in this promise of previously published data,
as studies demonstrating evidence of CARD15 as a suscep-
tibility gene for CRC, named Kurzawski et al. [15] and
Papaconstantinou et al. [16], feature relatively low patient
numbers.
Conclusion
In conclusion, common variants of the innate immunity
genes CARD4, CARD8 and CARD15 are not associated
with susceptibility to CRC in German population. In
accordance with previous studies, these findings suggest
that such variants are unlikey to play a major role disease
development in the majority of CRC patients. However,
our findings suggest a different situation for CRC patients
with early disease manifestation. For this patient sub-BMC Gastroenterology 2009, 9:79 http://www.biomedcentral.com/1471-230X/9/79
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group CARD15 R702W was found to be significantly asso-
ciated with disease susceptibility. Independent studies are
also needed to examine the effect of CARD4 E266K in
early onset CRC patients.
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